Hyperkalemia

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia

NCT03087058 | PHASE 2 | INTERVENTIONAL

The purpose of this study is to evaluate the change in serum potassium levels from start of treatment to Day 14, when patiromer is administered at different doses, once daily, in children 2 - \< 18 years of age with chronic kidney disease (CKD) and hyperkalemia (too much potassium in the blood). Another purpose of the study is to evaluate the safety and tolerability of patiromer in children 2 - \< 18 years of age with CKD and hyperkalemia.

30 Sites

23 Participants

Recruiting

2 Years to 17 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Investigator Site

Palo Alto,California,United States,94394

Investigator Site

Kansas City,Kansas,United States,64108

Investigator Site

Baltimore,Maryland,United States,21287

Investigator Site

Bronx,New York,United States,10467

Investigator Site

Cincinnati,Ohio,United States,45229

Investigator Site

Pittsburgh,Pennsylvania,United States,15224

Investigator Site

Amarillo,Texas,United States,79106

Investigator Site

Dallas,Texas,United States,75235

Investigator Site

Houston,Texas,United States,77030

Investigator Site

Madison,Wisconsin,United States,53792

Investigator Site

Sofia,Bulgaria,1606

Investigator Site

Vancouver,British Columbia,Canada,V5Z4H4

Investigator Site

Tbilisi,Georgia,0121

Investigator Site

Tbilisi,Georgia,0144

Investigator Site

Tbilisi,Georgia,0159

Investigator Site

Tbilisi,Georgia,0159

Investigator Site

Tbilisi,Georgia,0159

Investigator Site

Essen,Germany,45147

Investigator Site

Hannover,Germany,30625

Investigator Site

Heidelberg,Germany,69120

Investiagor Site

Köln,Germany,50937

Investigator Site

Bialystok,Poland,15-274

Investigator Site

Gdansk,Poland,80-952

Investigator Site

Krakow,Poland,30-663

Investigator Site

Lodz,Poland,93-338

Investigator Site

Lublin,Poland,20-093

Investigator Site

Warsaw,Poland,02-091

Investigator Site

Dnipropetrovs'k,Ukraine,49000

Investigator Site

Kharkiv,Ukraine,61075

Investigator Site

Kyiv,Ukraine,04050

Study Eligibility Criteria

Inclusion Criteria

* Written assent (when applicable) and written informed consent by a legally authorized representative provided prior to participation in the study
* Age 2 - \<18 years old
* CKD defined by the estimated glomerular filtration rate (eGFR) \<90 mL/min/1.73m2, including renal transplant subjects, based on local creatinine measurement at screening
* Two potassium measurements of 5.1 to \< 6.5 mEq/L performed on separate days
* In the opinion of the study doctor, is expected to require treatment for hyperkalemia for at least 6 month
* If taking any renin-angiotensin-aldosterone system inhibitors (RAASi) beta blockers or diuretic medications, must be on a stable dose for at least 28 days prior to Screening
* Negative pregnancy test in females of child-bearing potential

Exclusion Criteria

* Pseudohyperkalemia due to hemolysis or to abnormally high numbers of platelets (\>500,000/mm3), leukocytes (\>70,000/mm3), or erythrocytes (hematocrit \>55%) at Screening based on results obtained locally
* Evidence of potassium-related electrocardiogram (ECG) changes at Screening
* Any of the following kidney conditions: maintenance hemodialysis or peritoneal dialysis, renal artery stenosis, and acute kidney injury or a history of acute renal insufficiency in the past 3 months
* Severe disorder of stomach or intestines including surgery that could affect gastrointestinal transit of the drug
* Increased liver enzymes (ALT, AST \> 3 times upper limit of normal) at Screening
* Active cancer, currently on cancer treatment or history of cancer in the past 2 years (except for non-melanoma skin cancer)
* Heart or liver transplant, or anticipated need for transplant during the study treatment period including a scheduled kidney transplant recipient. (Note: patients currently on a kidney transplant wait list are not excluded unless there is an identified donor).
* Alcohol abuse or substance use disorder within 1 year of Screening
* Subjects currently being treated with or having taken any one of the following medications (includes resins) in the 7 days prior to Screening: sodium or calcium polystyrene sulfonate, drospirenone
* Use of certain medications that can affect blood potassium levels if doses have not been stable for at least 14 days prior to Screening or if doses are anticipated to change during the 14-day PD / Dose Finding Phase
* Use of investigational product within 30 days of screening or within 5 half-lives, whichever is longer
* Known hypersensitivity to patiromer or its components
* In the opinion of the Investigator, any medical condition, uncontrolled systemic disease, or serious intercurrent illness that would significantly decrease study compliance or jeopardize the safety of the subject or potentially affect the quality of the data

Additional Studies

Additional studies can be found at ClinicalTrials.gov